{{medical}}
{{Distinguish|左旋安非他命|右旋安非他命|安非他命}}
{{expert}}
{{Expand language|time=2017-05-10T04:35:18+00:00}}
{{Infobox drug
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 418022579
| IUPAC_name = (2''S'')-2,6-diamino-''N''-[(2''S'')-1-phenylpropan-2-yl]hexanamide
| image = Lisdexamfetamine structure.svg
| width = 275
| image2 = Lisdexamfetamine ball-and-stick model.png

<!--Clinical data-->
| tradename =  <!-- 不会翻译 Tyvense, Elvanse, Venvanse, Vyvanse -->
| Drugs.com = {{drugs.com|monograph|lisdexamfetamine-dimesylate}}
| MedlinePlus = a607047
| pregnancy_AU = B3
| pregnancy_US = C
| dependency_liability = [[身体依赖|身体依赖]]: 无<br />[[精神依赖|精神依赖]]: 中等
| addiction_liability = 中等
| legal_US = Schedule II
| licence_US = Lisdexamfetamine
| legal_UK = Class B
| legal_CA = Schedule I
| legal_DE = Anlage III
| legal_AU = S8
| legal_status = Rx-only
| routes_of_administration = 口服（[[膠囊劑|胶囊]]）

<!--Pharmacokinetic data-->
| bioavailability = 96.4%<ref>{{cite web| title=Public Assessment Report Decentralised Procedure | url=http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con261790.pdf |publisher=Shire Pharmaceuticals Contracts Limited |accessdate=2014-08-23 | page=14}}</ref>
| metabolism = 起初由[[红血球|红血球]][[水解|水解]]。<br />余下的代谢过程同[[安非他命#药物代谢动力学|安非他命#药物代谢动力学]]。
| elimination_half-life = ≤1小时（[[前体药物|前体药物]]分子）<br />9至11小时（右旋安非他命）
| excretion = 肾脏：约2%
| onset = 2小时<ref name="Millichap: onset, peak, and duration">{{cite book | author = Millichap JG |  editor = Millichap JG | title = Attention Deficit Hyperactivity Disorder Handbook: A Physician's Guide to ADHD | year = 2010 | publisher = Springer | location = New York, USA | isbn = 9781441913968 | pages = 112 | edition = 2nd | chapter = Chapter 9: Medications for ADHD | quote = <br />Table 9.2 Dextroamphetamine formulations of stimulant medication<br />Dexedrine [Peak:2–3 h] [Duration:5–6 h] ...<br />Adderall [Peak:2–3 h] [Duration:5–7 h]<br />Dexedrine spansules [Peak:7–8 h] [Duration:12 h] ...<br />Adderall XR [Peak:7–8 h] [Duration:12 h]<br />Vyvanse [Peak:3–4 h] [Duration:12 h]}}</ref><ref name="XR onset-duration">{{cite journal | vauthors = Brams M, Mao AR, Doyle RL | title = Onset of efficacy of long-acting psychostimulants in pediatric attention-deficit/hyperactivity disorder | journal = Postgrad. Med. | volume = 120 | issue = 3 | pages = 69–88 | date = September 2008 | pmid = 18824827 | doi = 10.3810/pgm.2008.09.1909 | quote = Onset of efficacy was earliest for d-MPH-ER at 0.5 hours, followed by d, l-MPH-LA at 1 to 2 hours, MCD at 1.5 hours, d, l-MPH-OR at 1 to 2 hours, MAS-XR at 1.5 to 2 hours, MTS at 2 hours, and LDX at approximately 2 hours. ... MAS-XR, and LDX have a long duration of action at 12 hours postdose}}</ref>
| duration_of_action = 12 hours<ref name="Millichap: onset, peak, and duration" /><ref name="XR onset-duration" />

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|IUPHAR}}
| CAS_number = 608137-32-2
| ATC_prefix = N06
| ATC_suffix = BA12
| PubChem = 11597698
| DrugBank_Ref = {{drugbankcite|correct|Drugbank}}
| DrugBank = DB01255
| IUPHAR_ligand = 7213
| ChemSpiderID_Ref = {{chemspidercite|correct|Chemspider}}
| ChemSpiderID = 9772458
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = H645GUL8KJ
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1201222
| synonyms = ''Vyvanse''

<!--Chemical data-->
| C=15 | H=25 | N=3 | O=1
| molecular_weight = 263.378 g/mol
| smiles = O=C(N[C@H](Cc1ccccc1)C)[C@@H](N)CCCCN
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C15H25N3O/c1-12(11-13-7-3-2-4-8-13)18-15(19)14(17)9-5-6-10-16/h2-4,7-8,12,14H,5-6,9-11,16-17H2,1H3,(H,18,19)/t12-,14-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = VOBHXZCDAVEXEY-JSGCOSHPSA-N
}}

[[File:30mg_Vyvanse_capsules.JPG|302px]]

'''甲磺酸赖氨酸安非他命'''（{{lang-en|Lisdexamfetamine}}），名字来源为“[[離胺酸|離胺酸]]-[[右旋安非他命|右旋安非他命]]”，是 [[中樞神經系統|中樞神經系統]]（CNS）[[右旋安非他命|右旋安非他命]][[兴奋剂|刺激剂]]的[[前体药物|前体药物]]，一种{{tsl|en|substituted amphetamine|替代安非他命|安非他命类}}的{{tsl|en|substituted phenethylamine|替代苯乙胺|苯乙胺}}，用于治疗[[注意力不足過動症|注意力不足過動症]]（ADHD）和[[過胖暴食症|過胖暴食症]]。<ref name="Vyvanse Drug Insert">{{cite web | title=Vyvanse Prescribing Information | url=http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021977s036s037lbledt.pdf | work=United States Food and Drug Administration | publisher=Shire US Inc. | accessdate=2015-02-24 | date = January 2015}}</ref><ref name="Amph Uses">{{cite journal |vauthors=Heal DJ, Smith SL, Gosden J, Nutt DJ | title = Amphetamine, past and present – a pharmacological and clinical perspective | journal = J. Psychopharmacol. | volume = 27 | issue = 6 | pages = 479–496 |date=June 2013 | pmid = 23539642 | pmc = 3666194 | doi = 10.1177/0269881113482532 }}</ref>

==参考资料==
{{reflist}}

{{ADHD_pharmacotherapies}}
[[Category:药理学|Category:药理学]]